Bio Path Holdings Inc (BPTH)

[SJSTOCKSHARK]

2 Quarter talk new info:

2 centers beginning phase II with two more in the final stages and up to 7 centers total for phase II.

19 patients by the spring of 2017.

Anthony Price the financial director gave the financial results and Ulrich Mueller answered the questions. You can now listen to the replay from the website.

Repeat of the research news:

“We made significant progress advancing our clinical development programs during the second quarter. Specifically, we were pleased to announce a sponsored research agreement with Thomas Jefferson University to investigate our DNAbilize™ technology for the development of a brain cancer immunotherapy,” said Peter Nielsen, President and CEO of Bio-Path Holdings. “In addition, we advanced preparations for the efficacy portion of our Phase II program of BP1001 for the treatment of acute myeloid leukemia (AML). We have seven leading cancer centers committed to conducting this trial and look forward to dosing patients in the near term.”

They answered a few questions.

After 19 patients it will take a month or two to review the results. BP1002 IND filing towards the end of the year.

Protocol has been submitted so a month or two for full phase II in CML.

After the 19 patients in AML the FDA will determine if they will "registered" the trial for accelerated approval.

Peter seemed excited about the investigation our DNAbilize™ technology for the development of a brain cancer immunotherapy. There is little treatment available for these patients.